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In idiopathic Parkinson disease (IPD) sleep disorders are common and may antedate the
onset of parkinsonism. Based on the clinical similarities between IPD and Parkinson dis-
ease associated with LRRK2 gene mutations (LRRK2-PD), we aimed to characterize sleep
in parkinsonian and nonmanifesting LRRK2mutation carriers (NMC).
Methods
A comprehensive interview conducted by sleep specialists, validated sleep scales and
questionnaires, and video-polysomnography followed by multiple sleep latency test (MSLT)
assessed sleep in 18 LRRK2-PD (17 carrying G2019S and one R1441G mutations), 17
NMC (11 G2019S, three R1441G, three R1441C), 14 non-manifesting non-carriers
(NMNC) and 19 unrelated IPD.
Results
Sleep complaints were frequent in LRRK2-PD patients; 78% reported poor sleep quality,
33% sleep onset insomnia, 56% sleep fragmentation and 39% early awakening. Sleep
onset insomnia correlated with depressive symptoms and poor sleep quality. In LRRK2-PD,
excessive daytime sleepiness (EDS) was a complaint in 33% patients and short sleep laten-
cies on the MSLT, which are indicative of objective EDS, were found in 71%. Sleep attacks
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occurred in three LRRK2-PD patients and a narcoleptic phenotype was not observed. REM
sleep behavior disorder (RBD) was diagnosed in three LRRK2-PD. EDS and RBD were
always reported to start after the onset of parkinsonism in LRRK2-PD. In NMC, EDS was
rarely reported and RBD was absent. When compared to IPD, sleep onset insomnia was
more significantly frequent, EDS was similar, and RBD was less significantly frequent and
less severe in LRRK2-PD. In NMC, RBD was not detected and sleep complaints were
much less frequent than in LRRK2-PD. No differences were observed in sleep between
NMC and NMNC.
Conclusions
Sleep complaints are frequent in LRRK2-PDand show a pattern that when compared to IPD
is characterized by more frequent sleep onset insomnia, similar EDS and less prominent
RBD. Unlike in IPD, RBD and EDS seem to be not markers of the prodromal stage of
LRRK2-PD.
Introduction
Idiopathic Parkinson disease (IPD) is a neurodegenerative condition where neuronal loss in
the substantia nigra leads to motor symptoms. Patients with IPD also present a variety of non-
motor symptoms such as sleep disorders, hyposmia, depression, constipation, hallucinations
and dementia. Damage of brain structures outside the substantia nigra is the origin of certain
nonmotor symptoms and in some cases they may antedate parkinsonism onset in what has
been called the prodromal phase of PD [1].
Sleep disorders such as insomnia, excessive daytime sleepiness (EDS) and REM sleep behav-
ior disorder (RBD) are common in IPD. RBD, and possibly EDS, may antedate the onset of
parkinsonism in IPD. The origin of sleep disturbances in IPD is multifactorial and includes
damage of the brain structures that modulate sleep, the coexistence of symptoms that may dis-
rupt sleep onset and maintenance (e.g., depression, nocturnal immobility), and the effect of
some medications (e.g., dopaminergic agents, antidepressants). Identification and management
of sleep disorders in IPD is important since they frequently have a negative impact on quality
of life [2–4].
Mutations in the leucine-rich repeat kinase 2 gene (LRRK2) are associated with sporadic
and familial PD (LRRK2-PD)[5–6]. Penetrance of LRRK2 mutations is incomplete and age-
dependent, and therefore a proportion of asymptomatic individuals carrying mutations can be
at the premotor stage of LRRK2-PD[7]. When manifested, clinical expression of LRRK2-PD is
usually similar to IPD and consists of late onset levodopa-responsive parkinsonism, typical
complications of dopaminergic therapy, and nonmotor features including hyposmia and
depression[8–15].
Available data on sleep disturbances in individuals carrying LRRK2mutations is scarce.
Based on the clinical similarities between IPD and LRRK2-PD we hypothesized that those
sleep disorders occurring in IPD may also be present in LRRK2-PD. Also, we hypothesized
that sleep disorders that are known to occur in premotor IPD may also be present in LRRK2
mutation carriers who have not developed parkinsonism yet. In the current study we sought to
characterize the sleep disturbances occurring in parkinsonian and nonparkinsonianLRRK2
mutation carriers through subjective and objective measures of sleep. For comparative
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purposes, sleep data on LRRK2mutation carriers were compared with relatives who were non
carriers of LRRK2 mutations and with unrelated IPD patients.
Methods
Participants and genetic assessment
The current study comprises individuals in whom the assessment of the LRRK2 genetic status
was determined at the Hospital Clinic de Barcelona, Barcelona, Spain. The study was con-
ducted between January 2012 and September 2013 in the Hospital Clinic de Barcelona.
Sixty-eight subjects were consecutively enrolled in the study, irrespective for sleep com-
plaints. We included the following groups for evaluations and comparisons: 1) 18PD carriers
of LRRK2mutations (LRRK2-PD), 2) 17 first-degree relatives of LRRK2-PD patients who were
carriers of LRRK2 mutations and had no parkinsonism (non-manifesting carriers, NMC) and,
3) 14 relatives of LRRK2-PD patients who were negative for LRRK2 mutations and had no par-
kinsonism (non-manifesting non-carriers, NMNC). During routine visits at the movement dis-
orders clinic, we recruited a group of 19 IPD patients who were consecutively selected to match
the LRRK2-PD group in age, gender, disease duration and Hoehn and Yahr stage[16].
Diagnosis of PD was made according the UK Brain Bank Criteria[17]. Exclusion criteria in
LRRK2-PD and IPD groups were age at parkinsonism onset less than 30 years, Hoehn and
Yahr stage4[16], dementia[18], and therapy with deep brain stimulation, apomorphine con-
tinuous infusionor intestinal levodopa gel infusion. Exclusion criteria in the NMC and NMNC
groups were age less than 18 years, and presence of motor symptoms, a neurological disorder
or a disabling disease.
Genotyping of G2019S, R1441G and R1441C mutations in the LRRK2 gene was performed
on blood samples as previously described[9]. Patients with IPD were negative for mutations in
LRRK2 gene. LRRK2-PD patients were aware of their genetic status. Subjects in the NMC and
NMNC groups were unaware of their genetic status.
In each participant all clinical and sleep assessments were done during a 2-day period. The
ethical committee at our institution approved the study and all participants gave written
informed consent.
Clinical assessment
Movement disorders expert neurologists (CPS and DV) conducted a medical interview that
included demographic and clinical data, and current medications including calculation of total
L-Dopa equivalent daily dose[19]. At the time of assessment all drugs had been stable during the
previous month. Motor and non-motor features, as well as their impact on daily living activities,
were evaluated with the Movement Disorders Society Unified Parkinson Disease Rating Scale
(MDS-UPDRS parts I to IV)[20], Hoehn and Yahr scale[16], and Schwab and England activities
of daily living scale[21]. Motor phenotype subtype was classified in postural instability and gait
difficulty, tremor dominant, and indeterminate[22]. The impact of PD upon quality of life was
determined with the PD questionnaire (PDQ-39)[23]and anxiety and depression by means of
the Hospital Anxiety and Depression scale (HADS)[24]. Cognition was evaluated using the
Montreal Cognitive Assessment (MoCA)[25]and a score of less than 21 points was suggestive of
cognitive impairment (according to a cut-off score established in Spanish population)[26].
Sleep assessment
Sleep-related symptoms, video-polysomnography (V-PSG) and multiple sleep latency test
(MSLT) were evaluated by sleep specialists (AFA, CG, AI and JS) who were blind to the
Sleep in LRRK2Mutation Carriers
PLOS ONE | DOI:10.1371/journal.pone.0132368 July 15, 2015 3 / 20
participant category and genetic status (LRRK2-PD, IPD, NMC or NMNC). Sleep evaluation
included the following assessments:
1. Sleep-related symptomatology. This was examined with a comprehensive semi-
structured sleep interview conducted by sleep experts where the presence of the bed partner or
anyone who witnessed the patient’s sleep was encouraged to substantiate and complete the
patient sleep history. The interview covered sleep habits and complaints such as sleep onset
insomnia (difficulty falling asleep within 30 minutes or more), sleep fragmentation (more than
two awakenings lasting more than 15 minutes), early awakening (waking up at least two hours
earlier than desired), nocturnal akinesia (difficulty in turning over in bed), excessive daytime
sleepiness (EDS, inability to stay awake during the major periods of the day resulting in unin-
tended episodes of sleep), sleep attacks (episodes of sudden onset of sleep without warning),
nightmares and dream-enacting behaviors. According to the sleep interview these sleep com-
plaints were categorized as being present or absent in each participant. In addition, overall
sleep disturbances and nocturnal disability were evaluated with the Pittsburgh Sleep Quality
Index (PSQI)[27] and the modified Parkinson’s Disease Sleep Scale (PDSS-2)[28]. PSQI global
score6 points and PDSS-2 total score15 were indicative of poor sleep quality[27, 29].
Subjective EDS was also assessed by means of the Epworth Sleepiness Scale (ESS), where a
score11 points was suggestive of EDS[30]. Sleep attacks were also identified using the Inap-
propriate Sleep Composite Score (ISCS).[31].
Restless legs syndrome (RLS) was diagnosed according to the International Restless Legs
Syndrome Study Group criteria[32]. Individuals who fulfilled the four diagnostic criteria for
RLS were then interviewed to verify its presence and exclude potential RLS mimics (e.g., stiff-
ness, cramps, off periods). RLS severity was measured with the International RLS Study Group
Rating Scale[33].
REM sleep behavior disorder (RBD) was diagnosed according to the International Classifi-
cation of sleep disorders 3rd revision criteria (ICSD-III)[34]. In brief, RBD was diagnosed in
patients with a chronic history of dream-enacting behaviors (reported by the patient or the bed
partner) in whom video-polysomnography (V-PSG) demonstrated excessive electromyo-
graphic (EMG) activity in REM sleep (see below for V-PSG definition of “excessive EMG activ-
ity”) linked to abnormal vigorous movements. RBD was also diagnosed in patients who were
unaware of displaying dream-enacting behaviors but V-PSG demonstrated excessive EMG
activity in REM sleep associated with vigorous behaviors that are typical of RBD (e.g., promi-
nent body jerking, kicking, screaming)[34]. Besides, the RBD screening questionnaire
(RBDSQ) was administrated to assess its usefulness to detect true RBD in LRRK2mutation car-
riers[35]. A RBDSQ score5 in nonparkinsonian subjects and a RBDSQ score7 in parkinso-
nian subjects has been considered suggestive of RBD[36].
2. Video-polysomnography (V-PSG). This was performed in all participants with a digi-
tal polygraph (Deltamed, software version 2007, Paris, France) and consisted of electroenceph-
alogram (F3, F4, C3, C4, O1, and O2, referred to the contralateral ear), right and left electro-
oculograms, surface EMG of the mentalis muscle, surface EMG of the right and left flexor digi-
torum superficialis in the upper limbs, surface EMG of the right and left anterior tibialis in the
lower limbs, electrocardiogram, nasal and oral air-flow assessment, nasal pressure cannula,
thoracic and abdominal movement assessment, and measurement of oxyhemoglobin satura-
tion. Sleep stages were scored according to standard criteria with the allowance for REM sleep
without atonia[37]. Apneas, hypopneas, arousals and periodic leg movements in sleep (PLMS)
were scored according to standard criteria[37]. The apnea/hypopnea index (AHI) was defined
as the mean number of apneas and hypopneas per hour of sleep, the arousal index was defined
as the mean number of arousals per hour of sleep, and the PLMS index (PLMSI) was defined as
the number of PLMS per hour of sleep[37].
Sleep in LRRK2Mutation Carriers
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For the measurement of EMG activity in REM sleep we followed the SINBAR method[38]
where a trained neurologist (AFA) visually quantified “any” (tonic, phasic or a combination of
both) EMG activity in the mentalis muscle plus phasic EMG activity in the right and left flexor
digitorum superficialis muscles. Following this method,32% of 3-sec mini-epochs containing
EMG activity in REM sleep was considered “excessive EMG activity” and indicative of RBD
[38].
3. Multiple SleepLatency Test (MSLT). This test evaluated the presence of objective EDS.
The MSLT was performed according to standard criteria and consisted of five naps at 2-hour
intervals beginning two hours after the end of the V-PSG[39]. A mean sleep latency onset of
8 min was considered indicative of objective EDS[34]. A mean sleep latency of8 min plus
more than one sleep onset period (SOREMP) defined a narcoleptic phenotype[3].
Statistical analysis
Data are reported in mean, standard deviation, number and percentage. Quantitative variables
were analyzed using Student’s t-test for comparisons of two independent groups. Qualitative
variables were analyzed using χ2-test and the Fisher exact test, when appropriate. No imputa-
tion was made for missing data. Subjects missing values in a particular field were not included
in the analysis for that particular outcome. Secondary analysis controlling for confounders like
sleep-related drug intake (e.g., benzodiazepines, dopamine agents) was performed by means of
ANOVA or logistic regression in case of differences between groups. Pearson’s correlation
coefficients were used to examine in the LRRK2-PD group the association between variables
and sleep onset insomnia and a mean sleep latency onset8 on the MSLT. Two tailed P values
of less than 0.05 were considered to be significant. Statistical analyses were performed with
SPSS version 20.0 (IBM).
Results
The study comprised 18 LRRK2-PD subjects from 17 families (17 patients carrying the G2019S
mutation and one the R1414G mutation), 17 NMC from 13 families (11 G2019S, three
R1414G and three R1414C), 14 NMNC from nine families (11 relatives of LRRK2-PD patients
carrying the G1920S mutation, and three individuals from the same family of a R1441G
LRRK2-PD patient), and 19 unrelated IPD patients. All seven subjects with the R1441G muta-
tion (one LRRK2-PD, three NMC and three NMNC) were from the same family. The three
NMC subjects carrying the R1441C mutation were siblings. All participants included in this
study were Caucasian Spanish except one G2019S LRRK2-PD subject of North-African origin.
All participants lived in Northeast Spain (63 in Catalonia and five in Menorca). Demographic,
parkinsonian and sleep related clinical data, V-PSG data and comparisons between groups are
presented in Tables 1, 2 and 3.
Sleep in LRRK2-PD subjects
There were nine women and nine men with a mean age of 61.0 ± 11.2 years. Fourteen (78%)
subjects had PSQI6 and eight (44%) a PDSS-215, which are indicative of subjective poor
sleep quality. Six (33%) patients complained of sleep onset insomnia, ten (56%) of sleep frag-
mentation, nine (50%) of nocturnal akinesia, 11 (61%) of nocturia, and seven (39%) of early
awakening. Sleep onset insomnia correlated with HADS total score (r = 0.512, p = 0.003),
HADS depression score (r = 0.707, p = 0.001), PSQI score (r = 0.740, p<0.001) and PDSS-2
score (r = 0.688, p = 0.002).
Six (33%) patients complained of EDS andnone of them reported that this symptom ante-
dated the onset of motor symptoms. Of these six patients, four had an ESS score11. MSLT
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was performed in 17 LRRK2-PD subjects and 12(71%)(six women and six men, 11 carrying the
G2019S mutation and one the R1441G mutation) showed a mean sleep latency of8 minutes
on the MSLT, which is indicative of objective EDS. Only four of these 12 patients with abnor-
mal sleep latency on the MSLT complained of EDS. There was no correlation between the
mean sleep latency on the MSLT with any demographic, clinical and V-PSG variable such as
age, PD duration and severity, therapy with dopaminergics, antidepressants and
Table 1. Demographic and parkinsonian clinical data and comparisons between groups.
LRRK2-PD
(n = 18)











Age (years) 61.0 ± 11.2 63.1 ± 11.2 44.4 ± 12.3 50.8 ± 16.0 0.996 <0.001 0.557
Female gender n (%) 9 (50.0) 8 (42.1) 9 (52.3) 7 (50.0) 0.758 0.849 0.858
Body mass Index (Kg/
m2)
26.4 ± 3.7 26.4 ± 2.8 25.8 ± 2.7 24.4 ± 3.8 0.966 0.677 0.299
Age at PD diagnosis
(years)
53.2 ± 10.2 55.9 ± 11.2 NA NA 0.440 NA NA
PD duration (years) 7.8 ± 5.8 7.3 ± 3.7 NA NA 0.746 NA NA
L-dopa intake n (%) 11 (61.1) 11 (57.9) 0 (0.0) 0 (0.0) 0.860 NA NA
Dopaminergic agonist
intake n (%)
16 (88.8) 11 (57.9) 0 (0.0) 0 (0.0) 0.021 NA NA
L-Dopa daily equivalent
dose (mg)
871.4 ± 669.2 550.2 ± 478.9 0 ± 0 0 ± 0 0.109 NA NA
Antidepressants intake
n (%)
4 (22.2) 4 (21.0) 2 (11.7) 2 (14.3) 0.867 0.510 0.941
Benzodiazepine intake n
(%)
10 (55.5) 2 (10.5) 1 (5.8) 3 (21.4) 0.003 0.003 0.249
UPDRS-I score (n) 10.2 ± 7.4 12.3 ± 7.6 3.1 ± 4.2 3.0 ± 4.0 0.398 0.002 0.931
UPDRS- II score (n) 8.9 ± 5.2 11.6 ± 7.9 0.2 ± 0.4 0.3 ± 0.5 0.239 <0.001 0.605
UPDRS-III score (n) 14.4 ± 7.7 21.8 ± 10.8 1.1 ± 1.9 0.2 ± 0.4 0.022 <0.001 0.085
UPDRS-IV score (n) 2.3 ± 3.5 1.4 ± 2.3 0 ± 0 0 ± 0 0.329 0.015 NA
PIGD subtype n (%) 10 (55.5) 10 (52.6) NA NA 0.756 NA NA
Indeterminate subtype n
(%)
4 (22.2) 1 (5.3) NA NA
Tremor dominant subtype
n (%)
4 (22.2) 4 (21.0) NA NA
Hoehn and Yahr stage
(n)
2.0 ± 0.7 1.9 ± 0.6 0 ± 0 0 ± 0 0.931 0.036 0.600
Schwab and England
score (n)
86.1 ± 10.4 87.0 ± 10.8 100 ± 0 100 ± 0 0.797 <0.001 NA
PDQ-39 score (n) 35.9 ± 15.2 36.2 ± 23.3 5.5 ± 6.4 7.4 ± 9.4 0.960 <0.001 0.544
HADS total score (n) 12.2 ± 6.1 10.5 ± 4.7 8.9 ± 5.8 8.3 ± 6.7 0.346 0.116 0.804
HADS-anxiety score (n) 6.8 ± 3.8 6.4 ± 2.3 5.9 ± 3.5 5.6 ± 4.3 0.658 0.491 0.806
HADS-depression score
(n)
5.4 ± 3.2 4.3 ± 2.9 2.9 ± 2.5 2.8 ± 3.1 0.277 0.023 0.890
MoCA score (n) 24.2 ± 4.7 24.9 ± 2.4 26.3 ± 2.4 27.4 ± 1.9 0.714 0.108 0.192
Data are presented as mean, standard deviation, number and percentage.
HADS: Hospital Anxiety and Depression scale; IPD: Idiopathic Parkinson Disease; LRRK2-PD: LRRK2 Parkinson Disease; MoCA: Montreal Cognitive
Assessment; NA: Not applicable; NMC: Non-manifesting carriers; NMNC: Non-manifesting non-carriers; PDQ-39: 39-item Parkinson Disease
Questionnaire; PIGD: postural instability gait difficulty; PD: Parkinson disease; UPDRS: Unified Parkinson Disease Rating Scale.
doi:10.1371/journal.pone.0132368.t001
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benzodiazepines, pain, HADS score, PSQI score, PDSS-2 score, sleep complaints, body mass
index, nocturnal total sleep time, sleep efficiency, PLMI and AHI.
Three (17%) patients, two women and one man, reported sleep attacks occurring several
years after the onset of parkinsonism. One patient reported a temporal association between the
introduction of pramipexol and the onset of sleep attacks. His sleep efficiency on the V-PSG
was 93%, no apneas were detected, and the mean sleep latency on the MSLT was 1 min.
Another patient with sleep attacks was taking L-Dopa, pramipexol and alprazolam, the sleep
efficiency in the V-PSG was 70%, AHI was 19 and sleep latency on the MSLT was 4 min. The
remaining patient experiencing sleep attacks was receiving L-Dopa, pramipexol and escitalo-
pram, sleep efficiency in the V-PSG was 91%, AHI was 25, and sleep latency on the MSLT was
5 min.
None of the LRRK2-PD patients had a narcoleptic phenotype. None had two SOREMPs on
the MSLT. A single SOREMP was detected in one subject who was sleep and REM sleep
deprived (nocturnal PSG showed a sleep efficiency of 30%and REM sleep was not recorded).
Three (17%) unrelatedG2019SLRRK2-PD had RLS (Table 4). RLS severity was mild in one
patient, moderate in one and severe in one. One patient reported that RLS symptomatology
started before and two after parkinsonism onset.
In three patients REM sleep was not recorded during V-PSG (none of these three subjects
reported a history of dream-enacting behaviors suggestive of RBD). Three (17%) unrelated
LRRK2-PD G2019S carriers had RBD (Table 5). All three were men and had thepostural















PSQI score (n) 8.3 ± 3.5 5.7 ± 3.6 3.6 ± 3.3 4.4 ± 4.8 0.033 <0.001 0.590
PSQI score 6 n (%) 14 (77.7) 8 (42.1) 1 (5.8) 3 (21.4) 0.025 <0.001 0.330
PDSS-2 score (n) 14.4 ± 7.7 10.2 ± 6.9 6.3 ± 6.2 3.4 ± 6.2 0.102 0.003 0.226
PDSS-2 score 15 n (%) 8 (44.4) 6 (31.6) 2 (11.7) 1 (7.1) 0.486 0.060 1.00
Sleep onset insomnia n (%) 6 (33.3) 0 (0.0) 2 (11.7) 3 (21.4) 0.005 0.242 0.564
Sleep fragmentation n (%) 10 (55.5) 5 (26.3) 4 (23.5) 2 (14.3) 0.054 0.158 0.411
Early awakening n (%) 7 (38.8) 7 (36.8) 1 (5.8) 2 (14.3) 0.804 0.046 0.501
Nocturia n (%) 11 (61.1) 12 (63.1) 10 (58.8) 6 (42.9) 0.944 1.000 0.198
Nocturnal tremor n (%) 2 (11.1) 3 (15.8) 0 (0.0) 0 (0.0) 0.723 0.489 NA
Nocturnal rigidity n (%) 5 (27.7) 3 (15.8) 0 (0.0) 0 (0.0) 0.335 0.049 NA
Nocturnal akinesia n (%) 9 (50.0) 9 (47.4) 0 (0.0) 0 (0.0) 0.758 0.001 NA
Early morning dystonia n (%) 4 (22.2) 1 (5.3) 0 (0.0) 0 (0.0) 0.117 0.108 NA
Restless legs syndrome (%) 3 (16.6) 3 (15.8) 2 (11.7) 2 (14.3) 0.911 1.000 0.941
IRLSGRS score (n) 4.0 ± 8.0 1.0 ± 4.0 2.0 ± 5.0 2.0 ± 6.0 0.505 0.723 0.382
Excessive daytime
sleepiness complaint n (%)
6 (33.3) 9 (47.3) 3 (17.6) 0 (0) 0.463 0.442 0.077
ESS score (n) 7.8 ± 5.0 8.3 ± 2.7 7.3 ± 4.5 5.5 ± 2.2 0.756 0.766 0.171
ESS score 11 n (%) 4 (22.2) 5 (26.3) 4 (23.5) 0 (0.0) 1.00 1.000 0.100
Sleep attacks n (%) 3 (16.6) 1 (5.3) 0 (0.0) 0 (0.0) 0.242 0.233 NA
RBDSQ score (n) 3.1 ± 2.2 3.7 ± 2.6 2.7 ± 2.7 1.1 ± 1.9 0.395 0.648 0.072
Data are presented as mean, standard deviation, number and percentage.
ESS: Epworth Sleepiness Scale; IPD: Idiopathic Parkinson Disease; IRLSGRS: International Restless Legs Syndrome Study Group Scale; LRRK2-PD:
LRRK2 Parkinson Disease; NA: Not applicable; NMC: Non-manifesting carriers; NMNC: Non-manifesting non-carriers; PSQI: Pittsburg Sleep Quality
Index; PD: Parkinson disease; PDSS-2: Parkinson’s Disease Sleep Scale 2; RBD: REM sleep behavior disorder; RBDSQ: RBD screening questionnaire.
doi:10.1371/journal.pone.0132368.t002
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Table 3. Polysomnography and Multiple Sleep Latency Test data and comparisons between groups.
LRRK2-PD
(n = 18)









Age (years) 61.0 ± 11.2 63.1 ± 11.2 44.4 ± 12.3 50.8 ± 16.0 0.996 <0.001 0.557
Total sleep time (min) 362.8 ± 95.8 396.2 ± 81.3 411.4 ± 65.7 409.2 ± 49.5 0.174 0.107 0.471
Sleep efficiency (%) 75.0 ± 19.2 82.2 ± 16.0 83.9 ± 13.2 83.5 ± 11.0 0.187 0.177 0.498
Wake time after sleep
onset (min)
75.6 ± 66.7 70.2 ± 63.5 47.4 ± 37.0 54.1 ± 40.8 0.539 0.154 0.777
N1 (%) 15.2 ± 6.9 11.2 ± 6.1 18.1 ± 20.3 12.7 ± 4.0 0.047 0.583 0.896
N2 (%) 67.3 ± 9.2 62.2 ± 12.4 52.9 ± 13.4 59.3 ± 8.1 0.136 0.001 0.190
N3 (%) 6.9 ± 6.9 10.0 ± 8.3 14.1 ± 7.1 10.8 ± 5.5 0.195 0.006 0.206
REM sleep (%) 10.6 ± 7.4 16.5 ± 9.9 18.5 ± 6.1 17.2 ± 6.5 0.059 0.003 0.541
Arousal Index (n) 18.5 ± 13.4 19.2 ± 12.5 15.0 ± 11.1 18.1 ± 8.6 0.953 0.428 0.222
AHI (n) 9.0 ± 11.6 15.3 ± 15.4 10.0 ± 14.7 14.7 ± 17.8 0.054 0.826 0.485
AHI 15 n (%) 5 (27.7) 8 (42.1) 4 (23.5) 5 (35.7) 0.428 1.000 0.700
PLMSI (n) 7.2 ± 13.3 8.0 ± 13.4 3.3 ± 5.3 4.9 ± 7.6 0.274 0.284 0.835
PLMSI 15 n (%) 4 (22.2) 4 (21.0) 1 (5.8) 3 (21.4) 1.000 0.346 0.330
REM sleep behavior
disorder (%)
3 (16.6) 10 (52.6) 0 (0.0) 0 (0.0) 0.037 0.224 1.000
REM sleep 3- secmini-
epochs (n)
825.5 ± 584.7 909.9 ± 583.2 1264.3 ± 534 1079.4 ± 363 0.663 0.033 0.289
SINBAR EMG activity
(%)
12.2 ± 14.9 42.2 ± 25.6 8.7 ± 4.8 9.7 ± 7.9 <0.001 0.482 0.757
Mentalis EMG activity
(%)
10.1 ± 12.1 29.1 ± 24.1 5.5 ± 3.5 5.4 ± 3.8 0.009 0.169 0.958
Mentalisplus AT EMG
activity (%)
15.4 ± 15.6 41.4 ± 23.7 14.5 ± 8.9 8.5 ± 4.9 0.007 0.352 1.000
MSLT sleeplatency
(min)
6.5 ± 4.6 8.0 ± 4.9 9.3 ± 5.3 7.2 ± 4.3 0.334 0.119 0.371
MSLT sleep latency
<5min n (%)
7 (41.2)* 8 (42.1) 4 (23.5) 4 (28.6) 0.955 0.472 0.700
MSLT sleep
latency < 8min n (%)
12 (70.6)* 8 (42.1) 6 (35.3) 10 (71.4) 0.106 0.153 0.466
SOREMPs on MSLT n
(%)
1 (5.8)* 1 (5.3) 0 (0.0) 1 (7.1) 1.000 1.000 0.483
Data are presented as mean, standard deviation, number and percentage.
*MSLT was performed in 17 out of 18 LRRK2-PD patients since one refused to undergo this test. Percentages on MSLT measures are therefore based
on these 17 subjects.
AHI: Apnea-hipopnea index; LRRK2-PD: LRRK2 Parkinson disease; Mentalis: polysomnographic montage quantifying "any" (phasic and tonic) type of
EMG activity in the mentalis muscle during REM sleep, using 3-sec mini-epochs (the cut-off for patients with RBD is 18%)[38]; Mentalis plus AT:
polysomnographic montage quantifying "any" (phasic and tonic) type of EMG activity in the mentalis muscle plus phasic EMG activity in the right and left
anterior tibialis during REM sleep, using 3-sec mini-epochs (the cut-off for patients with RBD is 46.4%) [38]; MSLT: Multiple Sleep Latency Test; NMC:
non-manifesting carriers; NMNC: non-manifesting non-carriers; NA: Not applicable; PLMS: Periodic Leg Movements in Sleep; PLMSI: Periodic Leg
Movements in Sleep Index; RBD: REM Sleep Behavior Disorder; SINBAR: polysomnographic montage quantifying "any" (phasic or tonic) type of EMG
activity in the mentalis muscle and phasic EMG activity in the right and left flexor digitorumsuperficialis muscles during REM sleep, using 3-sec mini-
epochs (the cut-off for patients with RBD is 32%)[38]; SOREMPs: Sleep Onset REM Sleep Periods.
doi:10.1371/journal.pone.0132368.t003
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instability and gait difficulty motor subtype. In two, the onset of RBD was reported to occur 10
and 12 years after the onset of parkinsonism, respectively. These two patients were unaware of
displaying dream-enacting behaviors that were reported by their wives who did not link the
onset of RBD symptomatology with the introduction of any medication. The remaining RBD
patient had no bed partner, and he reported no dream recall and lack of abnormal sleep behav-
iors. However, V-PSG was demonstrative of RBD showing excessive EMG activity in REM
sleep linked to prominent body jerking and talking. One additional patient reported talking,
laughing and kicking and recalled dreams of being attacked and arguing with a RBDSQ score
of 8 points (which is suggestive of RBD). In this patient, however, V-PSG showed normal mus-
cle atonia in REM sleep (SINBAR EMG activity of 10%)and therefore RBD was ruled out[38].
V-PSG showed AHI of 65. Videotape analysis disclosed gesturing and talking that only
Table 5. LRRK2-Parkinson Disease patients with associated REM sleep behavior disorder.
Patient LRRK2-PD-2 LRRK2-PD-6 LRRK2-PD-10
Age (years), gender 56, male 75, male 71, male
LRRK2 mutation G2019S G2019S G2019S
Age at RBD onset (years) Unknown 74 68
Age at parkinsonism onset (years) 40 62 58
UPDRS-III score (n) 6 10 18
HoehnandYahr stage (n) 2 2.5 3
Motor subtype PIGD PIGD PIGD
Falls / Freezing Yes / No Yes / No Yes / Yes
Motor fluctuations Yes Yes Yes
LEDD (mg) 664 1674 1940
MoCA (n) 28 25 22
Hallucinations No No No
RBDSQ (n) 2 8 4
Unpleasant dream recall No Attacked and chased by someone,
attacked by animals
No
Presence of a bed partner No Yes Yes




by the bed partner
No Talking, screaming, biting the
bedpartner
Punching, kicking, knocking off the nightstand,
talking, screaming, moaning




Prominent body jerking, kicking Prominent limb jerking, screaming and
moaning
SINBAR EMG activity (%) 39.8 42.1 35.9
M + AT EMG activity (%) 39.4 42.8 36.8
Mentalis EMG activity (%) 28.3 37.4 32.4
LEDD: L-Dopa Equivalent daily dose; M+AT: polysomnographic montage quantifying "any" (tonic or phasic) type of EMG activity in the mentalis muscle
plus bilateral anterior tibialis phasic EMG activity in REM sleep, using 3-sec mini-epochs (the cut-off for patients with RBD is 46.4%)[38]; Mentalis: EMG
activity quantification of "any" (tonic and phasic) type of EMG activity in the mentalis muscle during REM sleep, using 3-sec mini-epochs (the cut-off for
patients with RBD is 18.2%.)[38]; MoCA: Montreal Cognitive Assessment; PIGD: postural instability gait difficulty motor subtype; SINBAR:
polysomnographyc montage quantifying "any" (tonic or phasic) type of EMG activity in the mentalis muscle and phasic EMG activity in the right and left
flexor digitorumsuperficialis muscles during REM sleep, using 3-sec mini-epochs (the cut-off for patients with RBD is 32%)[38]; RBD: REM sleep
behaviour disorder; RBDSQ: REM sleep behavior disorder screening questionnaire; UPDRS-III: Unified Parkinson Disease Rating Scale motor exam;
V-PSG: video-polysomnography.
doi:10.1371/journal.pone.0132368.t005
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occurred during arousals at the end of obstructive apneic events during REM sleep and to a
lesser extent during no-REM sleep. We concluded that this patient had severe obstructive sleep
apnea mimicking RBD symptomatology (“pseudo-RBD”)[40].
The LRRK2-PD patient carrying theR1441G mutation complained of early awakening but
he had no subjective EDS, no sleep attacks, no RLS, no RBD, and V-PSG showed sleep effi-
ciency of 95%, absence of apneas and PLMS, and sleep onset latency on the MSLT of 4 min
without SOREMPs.
Fig 1. Electromyographic activity in REM sleep. Bars represent the percentage of electromyographic activity found during REM sleep in the different
groups included in the study. Grey bars represent the percentage of electromyographic activity found in individuals who were diagnosed with RBD. White
bars represent the percentage of electromyographic activity found in individuals who had no RBD. The dotted transversal line indicates that 32% of
electromyographic activity is the cut-off value for the diagnosis of RBD according to the SINBARmethod. Electromyographic activity32% during REM
sleep is indicative of RBD[38]. IPD: Idiopathic Parkinson disease; LRRK2-PD: LRRK2 Parkinson disease; NMC: non-manifesting carriers; NMNC: non-
manifesting non-carriers; RBD: REM sleep behavior disorder; SINBAR: polysomnographic montage quantifying "any" (phasic or tonic) type of EMG activity in
the mentalis muscle and phasic EMG activity in the right and left flexor digitorum superficialis muscles during REM sleep using 3-sec mini-epochs.
doi:10.1371/journal.pone.0132368.g001
Sleep in LRRK2Mutation Carriers
PLOS ONE | DOI:10.1371/journal.pone.0132368 July 15, 2015 11 / 20
Table 6. Patients with idiopathic Parkinson Disease associated with REM sleep behavior disorder.
Patient IPD-01 IPD-02 IPD-04 IPD-06 IPD-08 IPD-010 IPD-14 IPD-18 IPD-19 IPD-20
Age (years),
gender
57, female 69, male 75, male 60, male 62, male 63, female 73, female 72, male 78, female 56, female
Age at RBD
onset (years)




42 64 74 49 56 56 68 62 65 52
UPDRS-III (n) 20 28 23 9 24 30 26 44 16 24
Hoehn and
Yahr stage (n)
2 2 1 2 2.5 2 3 2.5 2 1.5
Motor subtype Indeterminate TD TD PIGD PIGD PIGD PIGD PIGD PIGD TD
Falls / Freezing No / No No / No No / No Yes / No No / No No / No No / Yes No / Yes Yes / No No / No
Motor
fluctuations
Yes No No Yes Yes Yes No No Yes No
LEDD (mg) 410 120 100 773 900 700 775 960 1597 0
MoCA (n) ND ND 22 26 24 25 ND ND ND ND
Hallucinations No No No Yes No No Yes No Yes No










































































































































41.7 91.1 58.6 63.8 32.1 44.4 85.3 62.5 73.3 49.6
M + AT EMG
activity (%)
38.9 84.4 53.8 66.3 33.1 42.3 76.8 63.3 68.1 54.0
(Continued)
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Sleep in LRRK2-PD vs. IPD subjects
Compared to IPD, LRRK2-PD patients reported more frequently sleep onset insomnia
(p = 0.005), had greater (worse) PSQI score (p = 0.033) and PSQI6 (p = 0.025), more benzo-
diazepines usage (p = 0.003) and lower UPDRS-III score (p = 0.022). In a secondary analysis
controlled for benzodiazepine and dopamine agonist intake, UPDRS-III score (p = 0.012),
PSQI6 (p = 0.012), and PSQI and score (p = 0.056) were still significant but not sleep onset
insomnia (p = 0.998).
There were no differences between LRRK2-PD and IPD groups in percentage of patients
complaining of EDS, ESS score, mean sleep latency on the MSLT, and percentage of patients
with mean sleep latencies shorter than five and eight min on the MSLT.
Overall, the LRRK2-PD group had less EMG activity in REM sleep than the IPD group
(Fig 1). RBD was diagnosed in three (17%) patients with LRRK2-PD and in ten (53%) with
IPD (p = 0.034) (Tables 5 and 6). Among the patients with RBD, those with LRKK2-PD had
less EMG activity in REM sleep than those with IPD (Fig 1). Seven IPD patients with true RBD
had a RBDSQ score less than seven (which is suggestive of not having RBD according to this
instrument). One IPD patient reporting dream-enacting behaviours and nightmares had a
RBDSQ score of eight points (suggestive of RBD), but V-PSG demonstrated that he had not
RBD but severe obstructive sleep apnea (AHI = 69)mimicking this parasomnia (“pseudo
RBD”)[40].
Sleep in NMC of LRRK2mutations
Subjects were nine women and eight men with a mean age of 44.4 ± 12.3 years. Sleep com-
plaints in this group were not common. Only one subject had a PSQI6 and two a PDSS-2
15. Two complained of sleep onset insomnia, four of sleep fragmentation, one of early awak-
ening, two had RLS, and only one used benzodiazepines.
Four (23%) subjects complained of EDS and all four had an ESS score11. Sleep attacks
were not reported by any individual. The mean sleep latency on the MSLT was in the normal
range (9.3 ± 5.3 min) and SOREMPs did not occur. The mean sleep latency on the MSLT was
not correlated with any demographic, clinical, and PSG variable.
None of the NMC had RBD. One NMC with RLS reported dream-enacting behaviors (e.g.,
kicking, gesturing, talking) and nightmares (e.g., being attacked by animals, arguing with peo-
ple), and had a RBSQ score of 9points (suggestive of RBD). However, V-PSG detected normal
muscle atonia in REM sleep (SINBAR EMG activity of 10.7%) excluding RBD[38]. V-PSG
Table 6. (Continued)
Patient IPD-01 IPD-02 IPD-04 IPD-06 IPD-08 IPD-010 IPD-14 IPD-18 IPD-19 IPD-20
Mentalis EMG
activity (%)
21.7 83.4 37.7 43.5 6.9 38.3 72.0 35.4 58.7 43.7
LEDD: L-Dopa Equivalent daily dose; M+AT: polysomnographic montage quantifying "any" (tonic or phasic) type of EMG activity in the mentalis muscle
plus bilateral anterior tibialis phasic EMG activity in REM sleep, using 3-sec mini-epochs (the cut-off for patients with RBD is 46.4%)[38]; Mentalis: EMG
activity quantification of "any" (tonic and phasic) type of EMG activity in the mentalis muscle during REM sleep, using 3-sec mini-epochs (the cut-off for
patients with RBD is 18.2%[38]; MoCA: Montreal Cognitive Assessment; ND: not done; PIGD: postural instability gait difficulty motor subtype; SINBAR:
polysomnographyc montage quantifying "any" (tonic or phasic) type of EMG activity in the mentalis muscle and phasic EMG activity in the right and left
flexor digitorumsuperficialis muscles during REM sleep, using 3-sec mini-epochs (the cut-off for patients with RBD is 32%[38]; RBD: REM sleep behaviour
disorder; RBDSQ: REM sleep behavior disorder screening questionnaire; TD: tremor dominant motor subtype; UPDRS-III: Unified Parkinson Disease
Rating Scale motor exam; V-PSG: video-polysomnography.
doi:10.1371/journal.pone.0132368.t006
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showed a PLMSI of 29 where PLMS were associated with arousals and videotape analysis
showed that the leg movements also involved the trunk and upper limbs resulting in prominent
body jerking associated with arousals. We concluded that in this subject the RBD-like symp-
tomatology was likely to be secondary to PLMS (“pseudo-RBD”)[41].
Sleep in LRRK2-PD vs. NMC of LRRK2mutations
LRRK2-PD patients were older and had higher UPDRS-I-IV scores, HADS depression sub-
score, early awakening, PSQI score, PSQI6, PDSS-2 score and more benzodiazepine intake.
In PSG, LRRK2-PD subjects had higher percentage of N2, and lower percentages of N3 and
REM sleep than NMC.
Six LRRK2-PD patients and three NMC complained of EDS, and the mean ESS score was
similar between both groups. The mean sleep latency was shorter in the LRRK2-PD than in
NMC group but difference was not statistically significant (6.5 ± 4.6 vs. 9.3 ± 5.3 min;
p = 0.119). RBD was diagnosed in three LRRK2-PD patients and in none NMC.
Sleep in NMC vs. NMNC of LRRK2mutations
Demographic, clinical, PSG and MSLT variables were similar between these two groups.
Discussion
To the best of our knowledge, this is the first systematic study evaluating sleep disorders with
subjective measures (comprehensive sleep interview, validated sleep scales and questionnaires)
and objective tools (nocturnal V-PSG followed by MSLT) in LRRK2mutation carriers. The
study evaluated individuals who had developed motor symptoms(LRRK2-PD and IPD) and
NMC who are at risk to manifest PD. Despite the limited number of subjects included, we
believe that our findings are relevant considering the prevalence of LRRK2 mutation in the
general population[9, 11]. Subjects were not selected on the basis of any specific sleep com-
plaint or previous diagnosis of a sleep disorder. We found that sleep complaints were frequent
in LRRK2-PD and included sleep onset insomnia, sleep fragmentation and early awakening.
Short sleep onset latencies on the MSLT, indicative of objective EDS, were frequent. Sleep
attacks occurred in three LRRK2-PD patients and a narcoleptic phenotype was not observed
on the MSLT. RBD occurred in three LRRK2-PD patients. EDS and RBD were reported to start
after onset of parkinsonism. RLS, PLMS and obstructive sleep apnea were not prominent fea-
tures in LRRK2-PD. In NMC, EDS was rarely reported and RBD was absent, suggesting that
these sleep disorders are not premotor markers of LRRK2-PD.
Mutations in the LRRK2 gene are the most common cause of monogenic PD[11]. In Spain,
the most frequent LRRK2mutations are G2019S and R1441G mutations, the latter particularly
in the Basque Country (Northern Spain)[9, 13–14]. The motor phenotype of LRRK2-PD
resembles IPD and is characterized by parkinsonism of late onset that responds to L-Dopa
therapy and motor complications of dopaminergic therapy[11]. Nonmotor symptoms are
also frequent in LRRK2-PD although they may differ when compared to IPD. Olfactory dys-
function, constipation, cardiac sympathetic denervation and neuropsychological impairment
are less prevalent and less severe in LRRK2-PD than in IPD [13, 15, 42]. In contrast, depression
and worse color discrimination have been reported to occur more frequently in LRRK2-PD
[12, 43].
Previous studies reported that LRRK2-PD patients may complaint of sleep onset insomnia,
repeated awakenings and features suggestive of RBD[11, 13, 15, 43–45]. However, these studies
did not employ scales or questionnaires specifically designed to examine sleep, and V-PSG and
MSLT were not used to identify objectively sleep disorders like EDS and RBD. Overall, we have
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found the same sleep disorders in LRRK2-PD than those previously described in IPD (sleep
onset insomnia, fragmented sleep, early awakenings, EDS, sleep attacks and RBD) but with a
distinct pattern; sleep onset insomnia was more frequent, EDS was similar and RBDwas less
frequent and less severe in LRRK2-PD than in IPD.
Compared to IPD, sleep onset insomnia was more frequent in LRRK2-PD and it was associ-
ated with depressive symptoms and poor sleep quality. Of note, sleep onset insomnia in
LRRK2-PD was not linked to features such as age, gender,PD severity and duration, anxiety,
and cognitive status. These findings may suggest that difficulty falling asleep in LRRK2-PD
may be explained in part by depression. Our findings are consistent with other studies in
LRRK2-PD where sleep disorders, mainly sleep onset insomnia and repeated awakenings,
occurred in 65% of the cases[43]and they were related to depression[12, 43, 45].
EDS was investigated through subjective (sleep interview and ESS) and objective (MSLT)
measures[46–47]. All LRRK2-PD patients who complained of experiencing EDS reported that
parkinsonism preceded the onset of this symptom. MSLT in LRRK2-PD showed that an
increased level of daytime sleepiness is a common feature that is frequently misperceived by
patients themselves. The finding that subjects were unaware of being abnormally asleep has
also been reported in 13–47% IPD patients without complaints of EDS[48–50].
In LRRK2-PD, demographic, clinical and sleep variables did not distinguish between sub-
jects with abnormal and normal sleep latencies on the MSLT. Potential causes of EDS such as
PD duration and severity, pain, depressive symptoms, the use of benzodiazepines, antidepres-
sants or dopaminergic agents, and obstructive sleep apnea failed to reveal a relationship with
reduced sleep latency on the MSLT. This suggests that the origin of EDS in LRRK2-2 PD is an
intrinsic feature of the disease itself related to an abnormal sleep-wake control, and it is not the
result of nocturnal sleep abnormalities, parkinsonism, or any drug.
Sleep attacks were noticed by three subjects with LRRK2-PD. As previously described in
IPD, sleep attacks in our LRRK2-PD patients were linked to the introduction of a dopamine
agonist, obstructive sleep apnea or an increasedlevel of daytime sleepiness on the MSLT[3, 51].
In contrast to what has been reported in IPD[48, 51], SOREMPs were not common in LRRK2
mutation carriers. We did not identify a narcoleptic phenotype in any patient carrying LRRK2
mutations.
Three LRRK2-PD patients had RBD confirmed by V-PSG. The pathophysiology of RBD is
related to dysfunction of the brainstem nuclei that regulate REM sleep atonia, namelythe locus
subcoeruleus and the magnocellularis nucleus[52]. Postmortem studies have shown that these
nuclei are severely damaged in IPD associated with RBD[53]. To the best of our knowledge the
state of these nuclei has not been reported in LRRK2-PD postmortem reports[54]. Our study
showed that compared to RBD occurring in IPD, RBD in LRRK2-PD was less frequent and
had less EMG activity during REM sleep. Thus, it can be speculated that damage of the brain-
stem structures that regulate REM sleep atonia is less marked in LRRK2-PD than in IPD. This
might be attributed to the heterogeneous neuropathological substrate found in LRRK2-PD
[54].
All three LRRK2-PD patients with RBD were men, carried the G2019S mutation, had the
postural instability and gait difficulty motor subtype, no hallucinations, no cognitive
impairment and lack of a previous history of impulse control disorders. RBD symptomatology
developed several years after parkinsonism onset. All were unaware of displaying dream-
enacting behaviors that were described by their bed partners, a finding which is also common
in idiopathic RBD and RBD secondary to IPD and multiple system atrophy[53].
The diagnosis of RBD was based on clinical and V-PSG criteria showing excessive EMG
activity in REM sleep associated with vigorous behaviors. Only V-PSG was able to identify true
RBD patients that were unaware of displaying dream-enacting behaviors (false negatives) and
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to exclude RBD in subjects with other sleep disorders (severe obstructive sleep apnea and
prominent PLMS involving the trunk and upper limbs) who presented with dream-enacting
behaviors and nightmares (false positives, RBD mimics). This reflects that V-PSG is necessary
to diagnose RBD and that questionnaires, particularly when self-administrated, may be not
adequate.
The penetrance of LRRK2 mutations is incomplete and increases in an age dependent man-
ner[11]. In LRRK2mutation carriers mean age of PD diagnosis is 58 years, and the estimated
risk to develop PD ranges from 12% to 36% at 59 years,26% to 59% at 69 years, and 47% to
80% at 79 years[11, 55]. This indicates that asubstantial proportion of NMC with increased age
could bein the prodromal stage of LRRK2-PD. The study of NMC provides a unique opportu-
nity to characterize the premotor stage of LRRK2-PD and the search for markers of conversion.
Conversion markers in prodromal LRRK2-PD may prove useful when neuroprotective strate-
gies will become available. Available data suggest thathyposmia, depression and constipation
can be present in the premotor stage of LRRK2-PD and IPD[1, 7, 10, 12]. RBD is also a marker
of premotor IPD[52]. It is uncertain if EDS predicts IPD[4]. Two population-based studies in
the elderly showed that subjects who reported EDS had increased risk of developing IPD[56–
57]. However, most studies have demonstrated that EDS is uncommon in untreated de novo
IPD[58–60]. Our study in LRRK2mutation carriers did not show that RBD and EDS may be
features of prodromal LRRK2-PD. RBD was not detected in NMC and when present in
LRRK2-PD patients the onset of parkinsonism preceded the onset of RBD for several years.
The study of sleep disorders therefore does not seem to be useful to distinguishNMC who are
in the premotor stage of LRRK2-PD and are likely to develop PD during lifetime. However this
assumption should be taken with caution since in our study 1) the number of NMC included
in our study was relatively small, 2) the mean age of NMC was only of 44 years and these sub-
jects may still be somewhat far in time from conversion, and 3) clinical follow-up of our cohort
is needed. Further studies of a larger NMC cohort with longitudinal follow-up should permit
to assess if sleep disorders are markers for phenoconversion to PD.
In summary, our findings show that sleep disorders in LRRK2-PD are common. Sleep onset
insomnia was more frequent, EDS was similar and RBD was less frequent and severe in
LRRK2-PD than in IPD. RBD and EDS seem not to occur in the premotor stage of LRRK2-PD.
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